A global research-driven pharmaceutical company that discovers, develops, manufactures and markets a range of innovative products to improve human and animal health.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
They bought SGP on the cheap.
SGP has the pipeline and management that MRK needed.
MRK has the deep pockets to carry through with the drugs in the pipeline, SGP did not.
Now the question is:
Does MRK have the fortitude to do what has to be done with their own management.
We shall see.
IF done correctly MRK has the raw materials to become THE dominate drug company that they were many years ago.
I'm betting they do, pressure from shareholders would help too. Consolidation in the pharm biz seems to be the trend. They still pay a decent dividend while we wait; $1.52/sh current yield 4.17%. Another plus is the DRIP - buy your first share and every share without a broker. Dollar cost average or add to your holdings for as little as $50. Core pharm holding along with Pfizer, Bristol Meyers and Novo Nordisk in my portfolio